Moderna Receives FDA Fast Track Designation For mRNA Vaccine Against Novel Coronavirus

Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s mRNA vaccine candidate (mRNA-1273) against the novel coronavirus (SARS-CoV-2). Fast Track is designed to facilitate the development and expedite the review of therapies and vaccines for serious conditions and fill an unmet medical need.

On May 6, the FDA completed its review of the Company’s Investigational New Drug application for mRNA-1273 allowing it to . . .